Conference Calendar

Mark your calendar:

CHEST 2016

October 22 - October 26 | Los Angeles, CA

Find more details below ▼



We can’t wait to meet you at the next conference or convention that Sunovion will be attending in 2016. See the list below to find out where we’ll be and what we’re doing in 2016!


January 1-31


February 1-29


March 1-31

MAR 17-20

AMDA 2016 Conference


Gaylord Palms Resort & Convention Center
6000 W Osceola Pkwy
Kissimmee, FL 34746

Booth #509

Exhibit Details

March 17 - 18

March 17
11:00 AM - 7:00 PM

March 18
7:00 AM - 1:30 PM

Product Theater

COPD in the Long-term Care Setting:
A Case-based Discussion of Nebulized Therapy

Saturday, March 19
12:45 PM - 1:45 PM

Presented by

Dana Saffel, PharmD, CGP, CPh, FASCP
President and CEO
PharmaCare Strategies Inc.
Santa Rosa Beach, Florida



April 1-30

APR 11-13

Spring Hospital Pharmacy Conference


Hyatt Regency
265 Peachtree Street NE
Atlanta, GA 30303

Booth #604

Exhibit Details

April 11

12:00 PM - 4:00 PM


May 1-31

May 13-18

ATS 2016

American Thoracic Society


Moscone Center
South Building – Halls A-B-C
747 Howard Street
San Francisco, CA 94103

Booth #911

Exhibit Details

May 15 - 17

May 15th
8:00 AM – 2:45 PM

May 16th
8:00 AM – 2:45 PM

May 17th
8:00 AM – 2:45 PM

Product Theater

COPD is a Struggle. Let's Talk About a Maintenance Therapy Option.

Tuesday, May 17, 2016
12:30 PM - 1:00 PM

Presented by

Antonio Anzueto, MD
Professor of Medicine
University of Texas
Health Science Center at San Antonio
San Antonio, Texas


June 1-30


July 1-31


August 1-31


September 1-30

SEP 8-11

Eastern Pulmonary Conference


The Breakers Palm Beach
One South County Road
Palm Beach, FL 33480

Exhibit Details

September 9 - 10

September 9
7:00 AM - 1:00 PM

September 10
7:00 AM - 1:00 PM

Product Theater

Rethinking Approaches to COPD Management
Friday, September 9, 2016
7:00 AM - 7:45 AM

Presented by
Sleep Medicine and Lung Health Consultants
Pittsburgh, Pennsylvania



October 1-31

OCT 13-15

Pri-Med Midwest


Donald E. Stephens Convention Center
5555 North River Rd
Rosemont, IL 60018

Booth #617

Exhibit Details

October 13 - 15

Thursday, October 13
8:30 AM – 4:15 PM

Friday, October 14
8:30 AM – 4:15 PM

Saturday, October 15
8:30 AM – 1:00 PM

Product Theater

Rethinking Approaches to COPD Management
Wednesday, October 12, 2016
11:55 AM – 12:40 PM

Presented by
Donald Mahler, MD
Emeritus Professor of Medicine
Geisel School of Medicine at Dartmouth
Hanover, NH
Staff Pulmonologist and Director of Respiratory Services
Valley Regional Hospital
Claremont, NH

OCT 15-18

AARC Congress


Henry B. Gonzalez Convention Center
900 East Market Street
San Antonio, TX 78205

Booth #1001

Exhibit Details

October 15 – 17

October 15
11:00 AM – 4:00 PM

October 16
9:30 AM – 3:00 PM

October 17
9:30 AM – 2:00 PM

OCT 17-19

Fall Hospital Pharmacy Conference


Hyatt Regency O’Hare
9300 Bryn Mawr Avenue
Rosemont, IL 60018

Booth #202

Exhibit Details

October 17

12:00 PM - 4:00 PM

OCT 22-26

CHEST Conference


Los Angeles Convention Center
1201 South Figueroa Street
Los Angeles, CA 90015

Booth #2017

Exhibit Details

October 24 - 26

October 24
10:00 AM - 4:00 PM

October 25
10:00 AM - 3:00 PM

October 26
10:00 AM - 2:30 PM

Product Theater

Rethinking Approaches to COPD Management
Monday, October 24, 2016
10:15 AM - 11:00 AM

Presented by
Donald P. Tashkin, MD
Emeritus Professor of Medicine
Division of Pulmonary and Critical Care Medicine
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California


November 1-30


December 1-31

DEC 4-8

ASHP 2016 Midyear Clinical Meeting


Mandalay Bay Convention Center
Las Vegas, NV

Booth #2526

Exhibit Details

December 5 - 7

Monday, December 5
11:00AM - 3:00PM

Tuesday, December 6
11:00AM - 3:00PM

Wednesday, December 7
11:00AM - 2:00PM

DEC 8-11

Pri-Med East


John B. Hynes Veterans Memorial Convention Center
900 Boylston Street
Boston, MA 02115

Booth # TBD

Important Safety Information & Indication


Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including arformoterol, the active ingredient in BROVANA (see WARNINGS). The safety and efficacy of BROVANA in patients with asthma have not been established. All LABA, including BROVANA, are contraindicated in patients with asthma without use of a long-term asthma control medication (see CONTRAINDICATIONS).

BROVANA is not indicated for the treatment of acute episodes of bronchospasm, ie, rescue therapy, and does not replace fast-acting rescue inhalers. BROVANA should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition. 

BROVANA should not be used in conjunction with other inhaled, long-acting beta2-agonists. BROVANA should not be used with other medications containing long-acting beta2-agonists. Patients who have been taking inhaled short-acting beta2-agonists on a regular basis should be instructed to discontinue their regular use and to use them only for symptomatic relief for acute respiratory symptoms.

All LABA, including BROVANA, are contraindicated in patients with asthma without use of a long-term asthma control medication.

As with other inhaled beta2-agonists, BROVANA can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, BROVANA should be discontinued immediately and alternative therapy instituted.

BROVANA, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, blood pressure, and/or symptoms.

BROVANA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders or thyrotoxicosis; and in patients who are unusually responsive to sympathomimetic amines.

BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.

Overall efficacy of BROVANA was maintained throughout the 12-week trial duration. Some tolerance to the bronchodilator effect of BROVANA was observed after 6 weeks of dosing (at the end of the dosing interval), although the FEV1 improvement remained statistically significant. This was not accompanied by other clinical manifestations of tolerance.

The five most common adverse events reported with frequency ≥2% in patients taking BROVANA, and occurring more frequently than in patients taking placebo, were pain (8% vs 5%), chest pain (7% vs 6%), back pain (6% vs 2%), diarrhea (6% vs 4%), and sinusitis (5% vs 4%).

For additional information, please see the full Prescribing Information including Boxed Warning, and Medication Guide for BROVANA (arformoterol tartrate) Inhalation Solution, at

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

BROVANA® (arformoterol tartrate) Inhalation Solution is indicated for the long-term, twice-daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. BROVANA is for use by nebulization only.